| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Acrivon Therapeutics, Inc.$1.79
-0.13 (-6.51%)
D 39Pipeline Score Overvalued Pharma · Clinical
Market Cap
67.20 M
EPS
-2.00
P/E Ratio
-0.78 $
Value Trade
467.53 K
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
15.17 M
Operating CF
-20.54 M
Total Assets
107.83 M
Total Liabilities
12.32 M
Equity
95.52 M
D/E Ratio
12,345
-7.89 %
Week
-2.23 %
1 Month
11.46 %
3 Month
-23.91 %
6 Month
-86.89 %
5 Year
-86.89 %
All Time
Cash Data
Cash Position
97.74 M
Monthly Burn
6.85 M
Runway
12.3 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
276.20 K
52 Week Range
1.15 - 3.56
% held by Insiders
21.24 %
% held by Institutions
42.69 %
Enterprise Value
-28.12 M
Total Shares
31.56 M
Short %
8.43 %
Float Shares
14.39 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Acrivon Therapeutics, Inc.
126Total events
5Upcoming
24Tier-1 (high impact)
2022 – 2026Coverage
Upcoming catalysts 2
TBD
T2Enrollment Complete
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
◆Interim AnalysisACR-368FiledTrial
Subscribe to view catalyst details
TBD
◆Trial InitiationACR-368FiledTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-12-31 | ACR-368 | Phase 2 data readout | Phase 2 | — | – | – | – |
2024-12-31 | ACR-368 | Phase 2 data readout | Phase 2 | — | – | – | – |
2024-12-31 | ACR-368 | Phase 2 data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
D39
Pipeline Score $13M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.2x
rNPV / MCap Top 56%
Micro Cap (rank 402 of 912)
Percentile RankAcrivon Therapeutics, Inc. faces pipeline headwinds (39/100), with $337M risk-adjusted pipeline value, led by ACR-2316 in Specific Advanced Solid Tumors (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACR-2316 Small molecule | Specific Advanced Solid Tumors | Phase 1 | NCT06667141 | 5% | $273M | RECRUITING | 100 | STALLED | D (38) | Dec 12, 2026 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ACR-368 BreakthroughFast Track | serous endometrial cancer | Phase 2b | 2026-05-13 | cORR of 52% (N = 23) in serous EC subjects versus an ORR of 22% (N = 37) in non-serous EC subjects Read More | Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim anal Read More | |
ACR-368 BreakthroughFast Track | serous endometrial cancer | Phase 2b | 2026-05-13 | cORR of 52% (N = 23) in serous EC subjects versus an ORR of 22% (N = 37) in non-serous EC subjects Read More | Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim anal Read More | |
ACR-368 BreakthroughFast Track | serous endometrial cancer | Phase 2b | 2026-05-13 | cORR of 52% (N = 23) in serous EC subjects versus an ORR of 22% (N = 37) in non-serous EC subjects Read More | Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim anal Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ACRV
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ACRV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ACRVAcrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim anal
Acrivon Therapeutics reported its financial results for Q1 2026, highlighting the progress of its key clinical programs, ACR-368 and ACR-2316. The ACR-368 Phase 2b study for serous endometrial cancer is advancing with a simultaneous interim analysis planned for late 2026. Meanwhile, ACR-2316 exhibited initial favorable safety and activity data in challenging tumor types like small cell lung cancer. The company reports a cash position of $97.7 million, supporting operations into 2027.
Read more →ACRVAcrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall respo
Acrivon Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting promising data from its ACR-368 Phase 2b study which indicated a 52% confirmed overall response rate in serous endometrial cancer. The company has initiated an additional cohort in the study and expressed strong clinical momentum supported by positive key opinion leader commentary. Additionally, initial data from ACR-2316 has shown favorable tolerability and promising clinical activity in lung cancer. With a financial position allowing operations to continue into mid-2027, Acrivon appears well-positioned for future growth.
Read more →ACRV▼ -17.9%on this news
Forward-looking statements Certain information contained in this presentation and related webcast includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding o
Acrivon Therapeutics presented forward-looking statements regarding ACR-368 during its recent KOL panel discussion. The presentation highlighted ACR-368's potential as a treatment for endometrial cancer and the use of a novel biomarker test designed to predict patient response. Despite the optimistic outlook, the implications of the findings remain uncertain due to potential risks and the inherent unpredictability associated with clinical trials.
Read more →ACRV▼ -34.6%on this news
ACR-368 AND ACR-2316 CLINICAL DATA AND AP3
Acrivon Therapeutics provided clinical updates on ACR-368 and ACR-2316 during their January 2026 conference call, showcasing both molecules' potential in treating various cancers. ACR-368, a selective CHK1/2 inhibitor, indicates favorable outcomes in endometrial cancer with a new trial underway, while ACR-2316 has shown encouraging initial data. The company emphasized the effectiveness of its AP3 platform for precision drug development, though market challenges remain. Additionally, the outcomes of these programs are uncertain until more data is available from ongoing clinical trials.
Read more →ACRV▼ -34.6%on this news
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candida
Acrivon Therapeutics has reported positive data from its ongoing ACR-368 Phase 2b trial, showing an overall response rate of 39%, with significant results for patients with serous endometrial cancer. Additionally, the company has submitted a Phase 3 study protocol to the FDA for ACR-368 in combination with anti-PD-1 therapy. Preliminary findings from the Phase 1 study of ACR-2316 also indicate favorable tolerability and tumor shrinkage in some patients. The firm plans to expand its clinical trials into Europe, aiming for quicker patient enrollment.
Read more →ACRV▼ -9.2%on this news
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for
Acrivon Therapeutics reported its financial results for Q3 2025, highlighting the progression of its lead asset ACR-368 in a registrational-intent Phase 2b trial for endometrial cancer. The company is well-funded with $134.4 million in cash, which is expected to support its operations through mid-2027. Additionally, Acrivon is advancing ACR-2316, showing promising early clinical activity. However, the company's net loss indicates it is still navigating financial challenges as it advances its pipeline.
Read more →ACRVForward-looking statements Certain information contained in this presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding our future results of
Acrivon Therapeutics presented a corporate overview emphasizing its commitment to precision medicine through its Predictive Precision Proteomics (AP3) platform. The company highlights ongoing clinical trials and the potential of its drug candidates, notably ACR-368. However, it also cautions stakeholders about the inherent risks and uncertainties associated with forward-looking statements, which may not always predict actual outcomes. The management urges caution against placing undue reliance on these statements as they navigate future developments.
Read more →ACRVAcrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368
Acrivon Therapeutics reported its second quarter 2025 financial results, highlighting significant progress in clinical trials for its two lead assets, ACR-368 and ACR-2316. ACR-368 is in a registrational-intent Phase 2b trial for endometrial cancer, showing promising treatment responses. Meanwhile, ACR-2316 is advancing in Phase 1 trials with demonstrated initial activity and no observed dose-limiting toxicities. The company maintains a robust cash position of $147.6 million, which it anticipates will support operations into 2027.
Read more →ACRVAcrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and plat
Acrivon Therapeutics has reported its first-quarter financial results for 2025, highlighting positive interim data from the ACR-368 Phase 2b trial in endometrial cancer patients. The data demonstrated a confirmed overall response rate of 35% and effective treatment responses in previously refractory patients. The company also observed tumor shrinkage in patients treated with ACR-2316 and announced the appointment of Mansoor Raza Mirza, M.D. as the new chief medical officer. With a strong cash position of $164.8 million, Acrivon is well-positioned to continue advancing its clinical pipeline.
Read more →ACRV▼ -7.9%on this news
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer Distinguished, highly accomplished clinician with stellar track record
Acrivon Therapeutics has appointed Dr. Mansoor Raza Mirza as the new Chief Medical Officer, effective April 9, 2025. Dr. Mirza, a distinguished oncologist with extensive experience in gynecological oncology, will oversee clinical development including the Phase 2b ACR-368 trial for endometrial cancer and the Phase 1 ACR-2316 study. His appointment comes at a pivotal time for Acrivon, with promising clinical data for its drug candidates aiding in potential regulatory submissions.
Read more →ACRVAcrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, p
Acrivon Therapeutics reported significant updates regarding its drug candidates ACR-368 and ACR-2316, showcasing strong clinical data in endometrial cancer patients. The company highlighted a 35% confirmed overall response rate for ACR-368, exceeding previous treatment outcomes. ACR-2316 also displayed early clinical activity with tumor shrinkage observed in phase 1 trials. The firm faces challenges in prioritizing its clinical resources due to increased competition in ovarian cancer and reduced enrollment in bladder cancer studies. Additionally, they have extended their cash runway into 2027, aiding ongoing developmental efforts.
Read more →ACRVCORPORATE R&D EVENT
Acrivon Therapeutics conducted a corporate R&D event highlighting its AP3 Generative Phosphoproteomics platform designed to improve drug discovery and development. The event presented updates on its ongoing clinical programs, including the ACR-368 Phase 2 and ACR-2316 Phase 1 studies. The presentation featured contributions from prominent experts in oncology, underscoring collaborations that could enhance the company's research capabilities. However, the forward-looking statements also acknowledged various inherent risks and uncertainties in achieving projected outcomes.
Read more →ACRV▼ -5.5%on this news· ran to -25% by day 3
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignat
Acrivon Therapeutics reported promising financial results for Q3 2024, highlighting a confirmed overall response rate of 62.5% for ACR-368 in patients with high-grade endometrial cancer. Positive data from the ongoing Phase 2b study was presented at ESMO, indicating significant potential for ACR-368 to address unmet needs in this patient population. Additionally, the company reported a strong cash position of $202.8 million, allowing it to fund operations until the second half of 2026. However, Acrivon also noted an increased net loss for the quarter compared to the previous year.
Read more →ACRVAcrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - First patient dosed two quarters ahead of original
Acrivon Therapeutics has successfully dosed the first patient in a Phase 1 trial for ACR-2316, a WEE1/PKMYT1 inhibitor, two quarters ahead of schedule. This milestone highlights the swift progression of ACR-2316 attributable to the company's AP3 platform. The trial aims to evaluate the safety and tolerability of ACR-2316, with initial clinical data expected in the second half of 2025. Acrivon aims to address cancer treatment needs through its innovative precision medicine approach.
Read more →ACRV▼ -7.6%on this news
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome
Acrivon Therapeutics has reported positive data from its ongoing Phase 2 study of ACR-368, showing a 62.5% overall response rate in endometrial cancer patients. The data indicates potential accelerated regulatory approval for ACR-368 in this tumor type. Additionally, Acrivon announced that its next clinical candidate, ACR-2316, has received IND clearance from the FDA, with trial sites activated ahead of timeline projections. The company continues to leverage its AP3 platform to develop precision oncology medicines.
Read more →ACRVAcrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
Acrivon Therapeutics reported its financial results for the second quarter of 2024, highlighting advancements in their pipeline and technologies. The company announced a positive response rate for its lead candidate ACR-368, with plans to share further clinical data at the upcoming ESMO conference. Acrivon also informed investors about the initiation of a Phase 1 clinical study of ACR-2316 and successfully completed a $130 million financing round. Nevertheless, the company experienced an increase in losses and expenses compared to the previous year.
Read more →ACRVAcrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Acrivon Therapeutics reported its Q1 2024 financial results highlighting significant progress in its clinical pipeline, particularly with ACR-368 which achieved a confirmed response rate of 50% in a Phase 2 trial. The company accelerated the IND timeline for ACR-2316 and successfully completed a $130 million financing. While the company faces increased net losses and rising expenses, these developments reflect positive momentum in the precision oncology space, with notable potential for future growth.
Read more →ACRVCORPORATE R&D EVENT APRIL 24, 2024 ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3) OVERCOMING LIMITATIONS OF GENETICS-BASED PRECISION MEDICINE Forward-looking statements -looking statements Certain information contained in
Acrivon Therapeutics is set to present significant updates on its Predictive Precision Proteomics (AP3) platform during a corporate R&D event on April 24, 2024. This technology aims to bridge gaps in genomics-based precision medicine by identifying disease-driving pathways matching drug mechanisms. The company is also advancing its ACR-368 and ACR-2316 candidates in various clinical trial stages, targeting key cancer indications. However, the company acknowledges inherent risks in its forward-looking statements, underscoring the uncertainty of future trial outcomes.
Read more →ACRV▲ +62.8%on this news· ran to +76% by day 1
Acrivon Therapeutics Announces $130 Million Private Placement Financing
Acrivon Therapeutics has announced a successful private placement financing that will generate approximately $130 million to fund its clinical development efforts. This includes advancing its lead candidate, ACR-368, currently undergoing Phase 2 trials. Notably, the financing attracted both new and existing investors, signaling confidence in Acrivon's strategic direction. The company expects that the capital will sustain its operations into the second half of 2026 while supporting its innovative precision medicine platform.
Read more →ACRV▲ +10.6%on this news
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Acrivon Therapeutics has reported its financial results for the fourth quarter and full year 2023, highlighting continued progress in clinical trials and business development. The company has activated 66 clinical trial sites for its Phase 2 trial of ACR-368 and is advancing the exploratory Phase 2 portion for patients who are sensitive to the treatment. Additionally, ACR-2316 is showing robust activity in preclinical studies. However, the financial report reflects a substantial increase in net losses due to rising operational costs.
Read more →ACRV▼ -11.4%on this news
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
Acrivon Therapeutics has appointed Santhosh Palani, Ph.D., CFA, to its Board of Directors, enhancing its leadership team with his extensive experience in healthcare investments and drug development. Dr. Palani has a history of working with biotechnological companies and previously served at PFM Health Sciences and New Enterprise Associates. The company continues to develop its proprietary proteomics-based platform for precision oncology, recently focusing on its lead candidate ACR-368, which has received FDA Fast Track designation and Breakthrough Device designation for its companion diagnostic assay.
Read more →ACRVAcrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magov evi -Liebisch, Ph.D., J.D., to Board of Directors
Acrivon Therapeutics has appointed Ivana Magov evi-Liebisch, Ph.D., J.D., to its Board of Directors. With over 25 years of industry experience, she has led various strategic initiatives in biopharmaceutical companies, including successful partnerships and commercialization efforts. Acrivon is currently developing precision oncology medicines using its proprietary platform, with a focus on its lead candidate ACR-368, which is advancing into clinical trials. The company aims to improve patient outcomes through innovative therapy strategies.
Read more →ACRV▼ -19.2%on this news
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
Acrivon Therapeutics reported its financial results for Q3 2023, marking a net loss of $14.5 million, which is an increase from the prior year's loss. The company highlighted advancements in its clinical pipeline, including promising early clinical data for its candidate ACR-368 and news of an upcoming IND submission for ACR-2316. Acrivon continues to leverage its proprietary AP3 platform for developing precision oncology medicines, maintaining a robust cash position projected to sustain operations into 2025.
Read more →ACRVAcrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies
Acrivon Therapeutics has announced the development of ACR-2316, a novel dual inhibitor targeting WEE1 and PKMYT1, utilizing the company's AP3 platform for precision oncology. The compound has shown compelling anti-tumor activity during preclinical studies and is designed to overcome resistance mechanisms associated with existing inhibitors. Acrivon plans to submit an Investigational New Drug application by the fourth quarter of 2024 to commence monotherapy development tailored to patients predicted to respond to the drug. The focus on preclinical optimization illustrates the potential for ACR-2316 to address unmet needs in solid tumor treatments.
Read more →ACRV▲ +6.8%on this news
Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
Acrivon Therapeutics reported its financial results for the second quarter of 2023, highlighting significant achievements in both clinical and preclinical developments. The company's net loss rose to $13.9 million, primarily due to elevated research and development expenses. Acrivon is preparing for initial clinical data release for its lead candidate ACR-368 in the latter half of 2023 and has strengthened its leadership team. Financial reserves are expected to sustain operations until at least 2025, supporting future growth initiatives.
Read more →ACRV▲ +6.8%on this news
Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
Acrivon Therapeutics recently released its financial results for the first quarter of 2023, reporting a net loss of $12.8 million, compared to $7.2 million in the same quarter of 2022. The company highlighted the advancement of its precision oncology platform, AP3, which aims to optimize patient treatment by matching drug candidates with tumor sensitivity. Notably, Acrivon received Fast Track designation from the FDA for ACR-368 in specific cancer indications. With a strong cash position of $159.5 million, the company is set to continue its development efforts through 2024.
Read more →ACRVA Acr criv ivon on T T h h e e r r a a p p e e u u t t ii c c s s ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3): DRUG-TAILORED PATIENT SELECTION FOR CLINIC AL SUCCESS INVESTOR EVENT MAY 01, 2023 F O R W A R D - L O O K I
Acrivon Therapeutics held an investor event on May 1, 2023, during which they provided an update on their Predictive Precision Proteomics (AP3) platform, aimed at enhancing patient selection for clinical trials. The platform utilizes predictive pulmonary proteomics to determine the best possible therapeutic responses in patients. The event outlined advancements in their clinical pipeline, specifically regarding the ACR-368 (Prexasertib) drug, which is in various stages of trial for different cancer types. The session highlighted the importance of drug-tailored patient selection to increase the likelihood of clinical success.
Read more →ACRVAcriv Acrivon on Thera Therapeutics peutics ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3): DRUG-TAILORED PATIENT SELECTION FOR CLINIC AL SUCCESS CORPORATE PRESENTATION APRIL 2023 ACRIVON THERAPEUTICS: DRUG -TAILORED PATI
Acrivon Therapeutics presented their AP3 platform, focusing on drug-tailored patient selection to enhance clinical success rates. The platform employs predictive proteomics to identify suitable candidates for treatments, aiming to overcome challenges in bringing clinically active drugs to market. The company showcased its pipeline, particularly ACR-368, which has demonstrated efficacy in several cancer types, including platinum-resistant ovarian cancer. Acrivon is targeting a broader patient population and enhancing precision oncology approaches.
Read more →ACRVAcrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Acrivon Therapeutics announced its fourth quarter and full year 2022 financial results, showing a significant increase in net loss compared to 2021, amounting to $31.2 million. The company highlighted its successful IPO on NASDAQ and FDA clearance for its Phase 2 trial of ACR-368, aimed at treating platinum-resistant ovarian, endometrial, and bladder cancers. With a strong cash position of $169.6 million, Acrivon anticipates funding operations into the fourth quarter of 2024, despite increased costs associated with clinical trials and public company operations.
Read more →ACRV▲ +5.1%on this news
Acriv Acrivon on Thera Therapeutics peutics ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3): DRUG-TAILORED PATIENT SELECTION FOR CLINIC AL SUCCESS MARCH, 2023 ACRIVON THERAPEUTICS: DRUG -TAILORED PATIENT SELECTION AIMING T
Acrivon Therapeutics is advancing its ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3) platform, designed for improved patient selection in oncology. The platform has indicated strong potential with objective response rates of 47% in previous trials of ACR-368, a CHK1/2 inhibitor, targeting difficult-to-treat cancers. Acrivon's approach may fill a significant gap in precision medicine, addressing the unmet needs of over 95% of cancer patients who could benefit from tailored therapies.
Read more →ACRVSHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT (this Agreement ) is entered into as of
SHARE PURCHASE AGREEMENT PURCHASE AGREEMENT (this Agreement ) is entered into as of November 14, 2022 (the Effective Date ), by and between Chione Limited (the Investor ), and Acrivon Therapeutics, Inc., a Delaware corporation (the Company ). WHEREAS, the Company is proposing
Read more →Competitive Position
How ACRV ranks across every disease it competes inCompetitive Position is a premium feature
See how ACRV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial